Fre­quen­cy Ther­a­peu­tics gets a $32M start­up round to help fine tune its hear­ing loss drug R&D

A re­cent ar­rival in the new wave of re­gen­er­a­tive med­i­cine 2.0 biotechs tak­ing shape has now col­lect­ed a $32 mil­lion Se­ries A for the next stage of de­vel­op­ment.

Woburn, MA-based Fre­quen­cy Ther­a­peu­tics now has the cash to see it through the next 12 to 18 months, says CEO David Lucchi­no, as the com­pa­ny steers its way to the clin­ic with their lead drug for hear­ing loss.

In­spired by the re­search of MIT’s Bob Langer and Har­vard’s Jef­frey Karp, Fre­quen­cy is de­vel­op­ing small mol­e­cule drugs de­signed to spark the re­growth of sen­so­ry hair cells in the in­ner ear, look­ing to re­store hear­ing dam­aged by noise.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.